Abstract: There are disclosed psychedelic and entactogen compounds, the use of such compounds in the treatment of diseases associated with a serotonin receptor or monoamine transporter, pharmaceutical compositions such as tablet compositions and kits containing the compounds, methods of delivering the compounds in a mist via inhalation, and methods of treating diseases or disorders associated with a serotonin receptor or monoamine transporter, such as inflammation, central nervous system (CNS) disorders or psychological disorders with the compounds of the invention.

Abstract: The present disclosure relates generally to methods of treating various diseases, disorders, and conditions, such as depressive disorders (e.g., Major Depressive Disorder (MDD)), substance use disorders, anxiety disorders, eating disorders, pain, and headache disorders via administration of deuterated psilocin and pharmaceutically acceptable salts, polymorphs, or solvates thereof.

Abstract: There are disclosed pharmaceutically acceptable salts of tryptamine compounds, the use of such salt forms in the treatment of diseases associated with a serotonin 5-HT2 receptor, pharmaceutical compositions such as those adapted for inhalation administration containing the salt forms, methods of delivering the pharmaceutically acceptable salt forms (e.g., via inhalation), and methods of treating diseases or disorders associated with a serotonin 5-HT2 receptor, such as central nervous system (CNS) disorders or psychological disorders, with the salt forms.

Abstract: The present disclosure relates generally to methods of treating various diseases, disorders, and conditions, such as depressive disorders (e.g., Major Depressive Disorder (MDD)), substance use disorders, anxiety disorders, eating disorders, pain, and headache disorders via administration of deuterated psilocin and pharmaceutically acceptable salts, polymorphs, or solvates thereof.

Abstract: The present disclosure relates to stable pharmaceutical compositions of amorphous psilocybin and deuterated psilocybin, and to the use of such pharmaceutical compositions in the treatment of diseases associated with a serotonin 5-HT2 receptor. The pharmaceutical compositions are formulated with solid dispersions of psilocybin or deuterated psilocybin in amorphous form dispersed in a polymer.

Abstract: The present disclosure relates to psilocin compounds and pharmaceutically acceptable salts, polymorphs, stereoisomers, or solvates thereof, to pharmaceutical compositions, and in some embodiments, to serotonin 5-HT2 receptor agonists and uses in the treatment of diseases associated with a 5-HT2 receptor.

Abstract: Provided herein is an ophthalmic formulation that comprises a fine particle of an A1 agonist in an aqueous suspension and a manufacturing process thereof. More specifically, provided herein is a topically applied ophthalmic aqueous suspension which is obtainable by suspending a fine particle of an A1 agonist in a surfactant and preservative; a method of reduction of intraocular pressure using the formulation and a manufacturing process of the aqueous suspension thereof.

Abstract: Novel thioglycerol derivatives, processes for their manufacture, and optical materials made from such compounds. The thioglycerol derivatives have high concentrations of sulfur relative to compounds conventionally used for optical materials, and thus exhibit high refractive indices without sacrificing processability.

Abstract: Novel thioglycerol derivatives, processes for their manufacture, and optical materials made from such compounds. The thioglycerol derivatives have high concentrations of sulfur relative to compounds conventionally used for optical materials, and thus exhibit high refractive indices without sacrificing processability.